FDA Approves Narcan for Over-the-Counter Sales

March 29, 2023 by Dan McCue
FDA Approves Narcan for Over-the-Counter Sales
The overdose-reversal drug Narcan is displayed during training for employees of the Public Health Management Corporation (PHMC), Dec. 4, 2018, in Philadelphia. (AP Photo/Matt Rourke, File)

WASHINGTON — The Food and Drug Administration on Wednesday approved the over-the-counter sale of a nasal spray that can reverse opioid overdoses, a move the agency says should save lives and reduce the nation’s surging rate of overdose deaths.

Narcan, a 4-milligram naloxone hydrochloride nasal spray, is the first product of its kind and is considered the standard when it comes to the treatment of an opioid overdose.

Wednesday’s approval had been sought by public health and treatment experts who believe greater availability of the drug could help turn the tide in drug fatalities. 

Earlier this month, a bipartisan group of 28 lawmakers on Capitol Hill joined the chorus, urging the agency to fully approve Narcan’s over-the-counter distribution.

With its approval, the rapid overdose treatment should be available in pharmacies, supermarkets and other retail stores by summer.

“Today’s approval of OTC naloxone nasal spray will help improve access to naloxone, increase the number of locations where it’s available and help reduce opioid overdose deaths throughout the country,” said FDA Commissioner Dr. Robert M. Califf, in a statement posted to the agency’s website.

“We encourage the manufacturer to make accessibility to the product a priority by making it available as soon as possible and at an affordable price,” he said.

According to a report released earlier this month by the Reagan-Udall Foundation for the FDA, in collaboration with the agency, opioid overdose persists as a major public health issue in the United States, with rates increasing substantially since 2013.

The report’s authors found that fatal opioid overdoses increased by 13% from 2020 to 2021, largely driven by increases in deaths due to fentanyl and its analogs.

“Every day, 187 people die from an opioid overdose, 24% of which involve prescription medication,” the report says.

Narcan/naloxone  prevents death from overdose by blocking the effect of opioids in the body. 

The reversal effects of the drug are temporary — restoring breathing within 2-3 minutes with effects lasting 30-90 minutes, and more than one dose of naloxone may be necessary to prevent death from an overdose depending on the amount of opioid ingested.

Prior to Wednesday, one of the challenges related to dealing with opioid overdoses was that reversal agents are most useful if present and administered at the scene of an overdose.

According to the Centers for Disease Control and Prevention and others, bystanders were present but unable to provide a lifesaving dose of Narcan/naloxone in at least 46% of fatal overdoses in 2021.

While states have allowed pharmacists to have a standing prescription of Narcan on hand so that they can quickly dispense it to anyone in need, pharmacies have been slow to act for factors ranging from cost and supply chain issues to concern that they are somehow enabling addiction.

Though opioid overdoses increased during the COVID-19 pandemic — and disproportionately so for Black Americans and residents of poor, urban areas — the number of naloxone prescriptions dispensed per week declined and remained low.

Of the nearly 17 million naloxone doses distributed in 2021, only 2.64 million were from pharmacies, the Reagan-Udall Foundation report said.

At present, a two-dose pack of prescription Narcan is often free to people covered by Medicaid or private insurance, or has a copay of less than $10. 

One concern, however, is that a typical health insurance plan prescription drug benefit, whether public or private, may not include coverage of nonprescription products, thus increasing out-of-pocket cost to the consumer if the nonprescription price is greater than a drug benefit copay.

Officials on Wednesday said how public and private insurance programs will deal with the new over-the-counter designation of Narcan could take weeks or months to work out.

In their letter to Califf, the 28 members of Congress wrote that “the reality is that overdose deaths are preventable, but intervention must occur quickly.”

“Putting Narcan directly into the hands of those impacted by substance abuse disorders will save countless lives,” they continued. “We consider this to be a step in the right direction, but acknowledge there is still more work to be done. We look forward to further action from the FDA on this issue, and we stand ready to work with you on further policies to end the opioid epidemic.”

Dan can be reached at [email protected] and at https://twitter.com/DanMcCue

A+
a-
  • Narcan
  • In The News

    Health

    Voting

    Health

    Biden Announcing New Rule to Protect Consumers Who Purchase Short-Term Health Insurance Plans

    President Joe Biden on Thursday announced new steps to protect consumers who buy short-term health insurance plans that critics say amount to junk. A... Read More

    President Joe Biden on Thursday announced new steps to protect consumers who buy short-term health insurance plans that critics say amount to junk. A new rule finalized by the Democratic president's administration will limit these plans to just three months. And the plans can only be renewed for a maximum... Read More

    March 27, 2024
    by Dan McCue
    One-Time Treatment Could Revitalize Immune Systems in the Elderly

    PALO ALTO, Calif. — A new study suggests that a one-time treatment that modulates the composition of a type of... Read More

    PALO ALTO, Calif. — A new study suggests that a one-time treatment that modulates the composition of a type of immune cell could potentially revitalize the immune systems of the elderly, helping their bodies better react to viral and bacterial threats. The research was carried out... Read More

    March 27, 2024
    by Dan McCue
    Insurers to Expand Access to ‘Navigation Services’ for Cancer Patients

    WASHINGTON — Seven of the nation’s largest health insurance companies are expanding access to so-called “navigation services” to help patients... Read More

    WASHINGTON — Seven of the nation’s largest health insurance companies are expanding access to so-called “navigation services” to help patients and their families navigate the myriad challenges that might arise during treatment for cancer and other serious illnesses. The insurers involved are Aetna; Blue Cross Blue... Read More

    Five Takeaways From the Abortion Pill Case Before US Supreme Court

    WASHINGTON (AP) — U.S. Supreme Court justices on Tuesday did not appear ready to limit access to the abortion pill mifepristone,... Read More

    WASHINGTON (AP) — U.S. Supreme Court justices on Tuesday did not appear ready to limit access to the abortion pill mifepristone, in a case that could have far-reaching implications for millions of American women and for scores of drugs regulated by the Food and Drug Administration. It's... Read More

    Biden and Harris Argue Democrats Will Preserve Health Care and Republicans Would Take It Away

    RALEIGH, N.C. (AP) — President Joe Biden and Vice President Kamala Harris on Tuesday promoted their health care agenda in... Read More

    RALEIGH, N.C. (AP) — President Joe Biden and Vice President Kamala Harris on Tuesday promoted their health care agenda in the battleground state of North Carolina, arguing that Democrats like themselves would preserve access to care while Republicans would reverse gains made over the past decade... Read More

    March 26, 2024
    by Tom Ramstack
    Supreme Court Skeptical of Ban on Abortion Pill Mifepristone

    WASHINGTON — A hearing Tuesday before the Supreme Court indicated a majority of the justices want to maintain women’s access... Read More

    WASHINGTON — A hearing Tuesday before the Supreme Court indicated a majority of the justices want to maintain women’s access to the abortion pill mifepristone despite objections from anti-abortion activists. The doctors and organizations who sued argued the Food and Drug Administration was wrong in granting... Read More

    News From The Well
    scroll top